Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis
The digital press release with multimedia content can be accessed here:
The digital press release with multimedia content can be accessed here:
The digital press release with multimedia content can be accessed here:
Read the original post:
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients...
NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September 17, 2020, on a virtual platform.
Read the original post:
Harrow Health to Attend Lake Street’s Virtual 4th Annual (BIG4) Conference September 17, 2020
Company announcement – No. 48 / 2020
Read more from the original source:
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
NEW YORK, NY, Sept. 11, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire – Todos Medical Ltd. (OTCQB: TOMDF), an in vitro diagnostics company focused on distributing comprehensive solutions for COVID-19 screening and diagnosis, and developing blood tests for the early detection of cancer and Alzheimer’s disease, today announced that the U.S. Food and Drug Administration (FDA) has added the TODOS 2019-nCoV RT-qPCR Detection Kit to its Notified List under the Emergency Use Authorization program. Todos is required to submit an Emergency Use Authorization application to the FDA within 15 days of submission of the notification.